Abstract
Introduction/Background* recent studies show that addition of anti-VEGF monoclonal antibody bevacizumab to platinum-based chemotherapy (P-CT) in advanced cervical cancer (ACC) treatment improves overall survival with an acceptable safety profile. The...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
